ACADIA Pharmaceuticals Q2 Earnings Call Highlights
Acadia Pharmaceuticals (NASDAQ:ACAD) raised its 2026 DAYBUE net sales guidance to $480 million to $510 million from $460 million to $490 million, citing expected initial European commercial sales in Q4. The company said the EMA CHMP issued a positive opinion for trofinetide and expects an EC decision later in Q3. Acadia kept 2026 NUPLAZID guidance at $760 million to $790 million and reported $956 million cash.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised DAYBUE 2026 net sales range, the CHMP positive opinion for trofinetide with an expected European Commission decision in Q3, and the updated R&D expense guidance alongside phase II top-line timing for remlifanserin (Sep-Oct).
Market read
Investors get concrete 2026 revenue guidance changes and multiple time-stamped catalysts (EU decision in Q3, Germany launch early Q4, remlifanserin data Sep-Oct).
What to watch
NUPLAZID growth is described as volume-driven with field-force ramp benefits; traders may discount sustainability if refill/restart rates or conversion gains fade after ramp.
Background
ACADIA’s Q2 call updates 2026 commercial guidance for DAYBUE and NUPLAZID, plus clinical timelines for remlifanserin (RADIANT) and trofinetide (Japan).
Ticker impact
ACADIA raised 2026 DAYBUE net sales guidance to $480M-$510M and expects EU launch in early Q4 after a positive CHMP opinion.
Bullish bias for ACAD shares, with follow-through risk tied to the European Commission decision timing and reimbursement approvals.
The article provides specific, time-bound guidance changes and a regulatory milestone (CHMP positive opinion) that directly affects expected EU commercialization and revenue mix.
Market effects
Reinforces investor focus on CNS specialty biopharma commercialization execution and EU regulatory progress for niche neurology drugs.
Highlights potential acceleration of European revenue contribution for a US-listed CNS franchise, contingent on reimbursement.
Supports broader confidence in cross-region expansion for CNS therapies, with Japan trofinetide data also flagged for Sep-Nov.
Counterpoint
EU launch and reimbursement remain uncertain; the raised guidance may already reflect expectations, limiting incremental upside if the European Commission decision or pricing drags.
Key entities
- companyACADIA Pharmaceuticals
US-listed CNS biopharma updating 2026 guidance and EU regulatory/clinical timelines on its Q2 earnings call.
- productDAYBUE (trofinetide)
ACADIA’s active ingredient received a positive CHMP opinion; EU launch timing and 2026 sales guidance were updated.
- productNUPLAZID (pimavanserin)
Commercial momentum described via prescription growth, field-force expansion, and maintained 2026 net sales guidance.
- pipeline_programremlifanserin
Phase II enrollment completed; top-line results expected Sep-Oct; Fast Track designation received.
